1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Liberty Latin America disclosed term sheets exchanged with holders of debt at its Liberty Puerto Rico (LPR) subsidiaries during restructuring talks, and said those negotiations are not continuing. The company states that no agreement has been reached and that none is assured, so the outcome for LLA shareholders remains unresolved. The proposals show that LLA's equity stake and the debt structure could change materially.
Term sheets are dated August 26, August 30, September 9 and September 11, 2026, and cover a restructuring of LPR debt, including a proposed $410 million of new money first-out notes at a 6.50% rate.
An LLA proposal of August 26, 2026 includes $1,250 million of second-out takeback debt at 8.00% and 25% of pro forma equity for LLA, plus warrants.
A SteerCo counterproposal dated August 30, 2026 shows LLA common equity as fully extinguished for no consideration.
LLA disputes any claim by LPR or its bondholders tied to about $410 million? No: LLA disputes any claim tied to distributions made from LPR bond proceeds, citing disclosures and records provided on August 28, September 1 and September 2, 20
authID entered a Backstop Commitment Agreement on September 9, 2026 with holders of its senior secured debentures, and $300,000 was funded on September 11, 2026. The agreement also fixes the debenture conversion price at $0.38, reduces existing warrant exercise prices from $1.50 to $0.57, and issues 750,000 commitment fee warrants, which could dilute shareholders. Share issuance under these securities is capped at 19.99% of prior outstanding shares absent stockholder approval.
Backstop commitment of up to $300,000 or $500,000, depending on whether a strategic investor funding transaction occurs; $300,000 was funded on September 11, 2026.
Existing warrant exercise price reduced from $1.50 to $0.57 per share; debenture conversion price fixed at $0.38.
750,000 commitment fee warrants issued at a $0.57 exercise price with a five-year term.
Nasdaq rules cap share issuance at 19.99% of shares outstanding before the April 29, 2026 purchase agreement without stockholder approval.
Beta Bionics said the FDA cleared its Mint patch pump and that it submitted a 510(k) application for its 3D Intelligence algorithm. It also lowered its 2026 full-year revenue estimate from $131 million to $136 million to $121 million to $126 million, citing a possible deferral of up to $10 million in the fourth quarter as new iLet users may wait for Mint. The filing also discloses a securities class action filed September 4, 2026, which the company says it intends to defend vigorously.
2026 total revenue estimate cut to $121 million to $126 million, from $131 million to $136 million; the company cites a deferral of up to $10 million in Q4 2026
Mint full U.S. commercial launch expected in Q1 2027, ahead of the previous target; manufacturing capacity of at least 1.5 million disposable units in 2027
Expected initial pharmacy coverage of about 40% of insured U.S. lives, rising to at least 50% within the first year of full commercialization
Holtzman v. Beta Bionics, Inc. securities class action filed September 4, 2026 in the Central District of California; potential loss not currently probable or estimable
Flag Ship Acquisition Corp, a blank-check company, signed a merger agreement on September 15, 2026 with Bluechip & Co. Holdings, a Cayman Islands holding company with insurance-related, advisory, advertising and data-center businesses. Bluechip shareholders would receive an aggregate of 40,000,000 Purchaser ordinary shares, reflecting a Company Net Value of $400,000,000, and the deal remains subject to shareholder approvals, a registration statement and Nasdaq listing approval.
Bluechip shareholders would receive an aggregate of 40,000,000 Purchaser ordinary shares, based on a Company Net Value of $400,000,000 at $10.00 per share.
Closing is subject to Flag Ship and Bluechip shareholder approvals, effectiveness of a Form F-4 registration statement, and Nasdaq Capital Market listing approval.
Expense loans from Bluechip to Flag Ship are non-interest-bearing and not due before June 20, 2027.
Post-closing board is expected to have five directors, including Bluechip CEO Ming Zhang.
RTX said Shane Eddy will step down as president of Pratt & Whitney effective January 1, 2027, and retire from the company at the end of the first quarter of 2027. Jill Albertelli, currently president of Pratt & Whitney's Military Engines business, has been named to succeed him. The change is a senior leadership transition for a major RTX business unit, with no financial results disclosed in the filing.
Shane Eddy steps down as Pratt & Whitney president effective January 1, 2027, and retires at the end of Q1 2027
Jill Albertelli, currently president of Pratt & Whitney Military Engines, succeeds him effective January 1, 2027
Eddy will remain with the company through March 2027 as a special advisor to support the transition
Albertelli reports to RTX chairman and CEO Chris Calio
Capital Southwest Corporation sold $350.0 million of 6.750% Notes due 2031 under an underwriting agreement dated September 10, 2026, and the offering closed September 15, 2026. The company expects net proceeds of about $342.1 million and plans to use them to repay part of its senior secured revolving credit facility, adding longer-term unsecured debt to its capital structure.
Principal amount: $350.0 million of 6.750% Notes due September 15, 2031
Net proceeds to the company: approximately $342.1 million at 98.985% of par, after a $3.5 million underwriting discount and about $0.9 million in estimated offering expenses
Proceeds intended to repay a portion of borrowings under the Corporate Credit Facility
Interest payable semi-annually on March 15 and September 15, beginning March 15, 2027
Dell subsidiaries Dell International L.L.C. and EMC Corporation completed a public offering of $5.0 billion in senior notes in four tranches, maturing from 2029 to 2037. The notes are unsecured and guaranteed by Dell Technologies Inc. and two of its wholly-owned subsidiaries, so the parent company's guarantee adds new direct obligations for shareholders to track.
Four tranches: $1.25 billion at 5.100% due 2029, $1.25 billion at 5.400% due 2031, $1.5 billion at 5.600% due 2033, and $1.0 billion at 5.900% due 2037.
Interest accrues from September 15, 2026, paid semi-annually, with the first payments due March 15, 2027 (2029, 2031, 2033 notes) and April 1, 2027 (2037 notes).
Notes are sold under a shelf registration statement on Form S-3ASR and governed by a base indenture dated January 24, 2023, with The Bank of New York Mellon Trust Company, N.A. as trustee.
Holders may require repurchase at 101% of principal upon a change of control triggering event.
Uranium Royalty Corp. reported results for the quarter ended July 31, 2026, with net income of $16.3 million, up from $1.0 million a year earlier, and diluted earnings per share of $0.10 versus $0.01. The company sold 593,255 pounds of U3O8 for $51.0 million revenue, and it used part of those proceeds to help finance its Sweetwater acquisition, completed in July 2026. Earnings rose sharply, but the filing gives no prior-year revenue or cost comparison and no guidance.
Revenue of $51.0 million from sales of 593,255 pounds of U3O8 at an average realized price of about $86.00 per pound
Net income of $16.3 million versus $1.0 million for the same period in 2025
Diluted EPS of $0.10 versus $0.01 a year earlier
Sweetwater acquisition completed in July 2026, partly funded by uranium sales
Harte Hanks disclosed that the go-shop period under its August 14, 2026 merger agreement with Star Equity Holdings has expired, and that it received Acquisition Proposals during that period and gave Star an Exempted Party designation notice on September 11, 2026. The Board has not determined that any proposal is a Superior Proposal and has reaffirmed its recommendation of the Star merger, so the Star deal remains in effect.
Go-shop period expired; the company solicited interest from 93 third parties and received Acquisition Proposals before expiration.
Exempted Party designation notice delivered to Star on September 11, 2026; Board has not determined any proposal is a Superior Proposal.
Star deal terms: $5.00 in cash or 0.50 shares of Star 10% Series A Cumulative Perpetual Preferred Stock per eligible share, with cash capped at $19.2 million.
Termination fee of $1,152,000 payable to Star if the company terminates to enter a Superior Proposal after the go-shop period.
Orion Energy Systems said a longtime US retailer customer made a follow-on commitment for a new LED lighting project estimated at $10 million to $15 million, and raised its fiscal 2027 revenue outlook to $100 million to $102 million from $95 million to $97 million. The company said the timing of individual purchase orders is uncertain, and that Q2 revenue is expected to fall from the previously announced Q1 revenue of $25.7 million.
FY 2027 revenue outlook raised to $100 million to $102 million, up from $95 million to $97 million
New retailer project estimated at $10 million to $15 million; most revenue expected in the second half of fiscal 2027, which ends March 31, 2027
Fiscal Q2 revenue expected to decrease compared with Q1 revenue of $25.7 million
Company continues to expect positive Adjusted EBITDA for the fiscal year as a whole
LifeMD announced an exclusive collaboration with AT&T under which eligible AT&T wireless and fiber customers receive a complimentary LifeMD membership, with the $19 monthly fee waived. The filing does not quantify expected revenue or costs, but it states that LifeMD will initially pay AT&T a fixed fee per lead, and that the agreement runs for an initial one-year term with automatic renewals.
Eligible AT&T customers receive a LifeMD membership with a $228 annual value; the $19 monthly fee is fully waived.
The initial launch covers 29 million AT&T customers in 11 states, with additional markets joining in January 2027 as the program expands nationwide.
LifeMD will pay AT&T a fixed fee per lead, with later compensation to be negotiated; the agreement has a one-year initial term with automatic one-year renewals unless either party gives 90 days' written notice.
Dream Finders Homes entered subscription agreements on September 14, 2026, selling 225,000 shares of Series B Convertible Preferred Stock for $225.0 million, and used the proceeds to redeem its Series A preferred stock. The company also agreed to sell 450,000 more Series B shares at a second closing, contingent on completing its previously announced merger with Beazer Homes USA, Inc., which would fund part of the merger consideration. The preferred stock ranks senior to common stock on dividends and liquidation, carries a 12.00% cumulative dividend, and can convert to Class A common stock at a discount after six years, so it adds a senior claim and potential dilution for common shareholders.
225,000 Series B shares sold at a first closing on September 14, 2026, for an aggregate $225.0 million, with a 2.50% original issue discount
Cumulative dividend of 12.00% per year, payable quarterly, with a maximum rate of 15.00% after step-ups
Additional 450,000 Series B shares to be sold at a second closing tied to the Beazer Homes USA merger conditions
Conversion not permitted by purchasers before the sixth anniversary of the First Closing, except in a Fundamental Change; conversion price floor of $4.19
WhiteHorse Finance said its board formed a special committee of independent directors to explore strategic alternatives, which could include a sale or other corporate transaction. The filing gives no timetable and says there is no assurance the review will lead to any transaction.
Board formed a special committee of independent directors on September 15, 2026
Review could include a sale or other corporate transaction
No timetable set; company will not comment further unless a course of action is approved, the review ends, or disclosure is required
Tredegar's board elected Cindy Yao as Vice President, Chief Financial Officer and Treasurer on September 14, 2026, effective September 21, 2026. The filing says the company is pursuing a transition from a holding-company structure toward an operating-company model, and the CEO said the new CFO will help with enterprise-level financial visibility and performance discipline.
Board elected Cindy Yao on September 14, 2026; start date is September 21, 2026
Annual base salary of $450,000, with a target bonus of 60% of base salary under the 2026 Short-Term Incentive Plan (maximum 120%)
Long-term incentive target of 80% of base salary, split 50% restricted stock and 50% non-equity cash
Prior roles include CFO of Holon Health from May 2026 and CFO of HF Foods Group from May 2024 through October 2025
5E Advanced Materials and its subsidiary 5E SVM agreed on September 14, 2026 to buy specified assets of Searles Valley Minerals and affiliates through a Section 363 sale in Chapter 11 bankruptcy, with consideration of about $3.4 million in cash, 8.3 million common shares, and a promissory note of about $6.2 million. The deal requires Bankruptcy Court approval, Surface Transportation Board authorization for railroad assets, and $10.0 million in bridge financing, and the company expects closing in early October 2026, which would add 8.3 million shares for shareholders and bring operating facilities, but the assets are being acquired as is and the sellers' representations will not survive closing.
5E SVM was selected as successful bidder on September 14, 2026 for assets including Argus, Westend and Trona facilities and about 9,000 acres of Searles Lake brine resources in San Bernardino County, California.
Consideration includes about $3.4 million in cash, 8.3 million shares of common stock, and a senior unsecured promissory note of about $6.2 million; a $300,000 deposit was made.
The company guarantees 5E SVM's cash payment obligation, and the Bridge Facility of $10.0 million carries 8.00% interest with a $1.0 million transaction fee.
The company expects closing in early October 2026; the outside date is October 2, 2026, extendable to October 16, 2026.
Cabot's board elected Vice President and Treasurer Steven J. Delahunt as Chief Financial Officer, effective October 1, 2026, on an interim basis. Erica McLaughlin, the current CFO, becomes President and Chief Executive Officer on the same date, succeeding Sean Keohane. The company is searching for a permanent CFO, and the filing contains no financial results.
Delahunt, who joined Cabot in 2010, serves as interim CFO effective October 1, 2026.
McLaughlin is elected President and CEO effective October 1, 2026, succeeding Sean Keohane.
Delahunt receives a monthly cash stipend of $35,000 while serving as interim CFO.
Delahunt was Vice President of Investor Relations from July 2016 through January 2026.
GT Biopharma entered into a securities purchase agreement on September 14, 2026, selling Series M 10% convertible preferred stock and warrants for an aggregate purchase price of $7,450,000, with up to $30,000,000 more available to purchasers through greenshoe rights. The preferred stock converts at an initial price of $6.10 per share and carries full ratchet price protection, so the potential dilution to existing shareholders could be substantial; the company also agreed to seek shareholder approval for issuances above 19.99% of outstanding common stock.
Aggregate purchase price of $7,450,000 for preferred stock and warrants with stated value of $8,277,778
Preferred stock and warrants have an initial price of $6.10 per share and full ratchet price protection
Purchasers may buy up to $33,333,333 of additional preferred stock for $30,000,000 under greenshoe rights
Company agreed to hold a stockholder meeting seeking approval for issuances above 19.99% of outstanding common stock
Scholar Rock disclosed that the FDA approved ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in adults and children 2 years and older receiving an SMN2-targeted treatment. The company also corrected management's statement during the September 14, 2026 investor call that the FDA required no post-marketing safety commitments, saying the FDA does require a pregnancy safety study and fracture alert reports.
FDA approved ISEMBYLD for SMA patients aged 2 and older currently on an SMN2-targeted treatment
FDA requires a post-marketing pregnancy safety study covering pregnancy complications and birth outcomes
FDA requested that all serious and non-serious fracture cases be submitted as 15-day alert reports
Correction was made to statements made in error during the September 14, 2026 investor call
Otis Worldwide said Chair, CEO and President Judith F. Marks will retire, effective on the earlier of her successor starting as CEO, expected in the first half of 2027, or July 31, 2027. A Board succession committee chaired by Christopher J. Kearney is searching internal and external candidates with Spencer Stuart, and the filing reports no financial results or guidance changes.
Judith F. Marks will resign from the Board on the Transition Date and from all other Company positions.
Transition Date is the earlier of her successor's start as CEO (expected first half of 2027) or July 31, 2027.
If the Transition Date falls before July 31, 2027, Marks serves as a non-employee senior advisor through that date with no cash compensation.
Her equity awards keep vesting during the advisory period, and she remains eligible for her 2026 annual bonus based on actual performance.
Lindblad Expeditions acquired a 60% controlling interest in White Desert, PNR Airways and Echo Charlie for about $61 million in cash, plus about $6 million for balance-sheet cash, subject to customary true-up adjustments. The company also raised its full-year 2026 revenue, net yield and Adjusted EBITDA guidance to reflect the deal and continued strong performance across the business.
60% controlling interest in White Desert, PNR Airways and Echo Charlie for about $61 million cash, plus about $6 million for balance-sheet cash
Options to buy the remaining equity in two equal tranches, exercisable within 30 days of December 31, 2030 and 2031, priced on the companies' EBITDA at the time
Updated 2026 guidance: tour revenues of $850 - $880 million, net yield per available guest night of 5.5% - 6.5%, Adjusted EBITDA of $140 - $148 million
CEO Natalya Leahy called the transaction the largest in the company's history
Driven Brands announced updated capital allocation priorities on September 15, 2026, including a $100 million share repurchase authorization effective that day and a long-term net leverage target of 2-3x Net Debt to Adjusted EBITDA. The company said it reduced net leverage from 5.0x at the end of 2023 to an expected 3.0x at the end of Q3 2026, and the buyback equals about 5% of its market capitalization, so the plan directly affects shareholder returns.
$100 million share repurchase authorization, effective September 15, 2026, with no stated expiration date
Company is not obligated to repurchase shares and may discontinue the program at any time; purchases will be funded from cash balances and cash flows
Net leverage target set at 2-3x Net Debt to Adjusted EBITDA; company expects 3.0x at end of Q3 2026, a quarter ahead of plan
Company will continue investing in Take 5 growth, which may include acquisitions where attractive
Connect Biopharma reported topline results from its 160-patient Phase 2 Seabreeze STAT Asthma study of rademikibart as an add-on to standard of care for acute asthma exacerbations. The primary endpoint, treatment failure over 28 days, did not reach statistical significance (p=0.153), although the company reported a 66% reduction versus placebo, while the key secondary endpoint, post-bronchodilator FEV1 at Day 7, was statistically significant (p=0.023). The company plans to report COPD study data later this month and then meet with the FDA on a Phase 3 program.
Treatment failure rate over 28 days was 2.5% (2 of 79) with rademikibart versus 7.4% (6 of 81) with placebo; p=0.153, not statistically significant
Post-bronchodilator FEV1 on Day 7 rose 250 mL with rademikibart versus 120 mL with placebo, a 130 mL difference (p=0.023)
One serious adverse event was reported in the rademikibart arm versus three in the placebo arm; no AEs led to study discontinuation in either arm
Seabreeze STAT COPD study topline data expected later in September 2026; company plans to engage the FDA on a Phase 3 program afterward
Vera Therapeutics announced that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 trial in adults with IgA nephropathy at risk for disease progression. The company reported a placebo-adjusted 52-week eGFR change of 5.6 mL/min/1.73m2 and a 76% reduction in risk of composite kidney disease progression, and plans to submit a supplemental BLA to the FDA in Q4 2026.
Final analysis set of 428 patients; 52-week eGFR treatment effect of 5.6 mL/min/1.73m2 versus placebo (p<0.0001)
Composite kidney disease progression through 104 weeks: 11 events on TRUTAKNA versus 38 on placebo, hazard ratio 0.24
Company plans to submit supplemental BLA to FDA in Q4 2026 for full approval, and reported over 350 patient start forms in the first ten weeks
Overall adverse event and infection rates were similar to placebo; infections were reported in 32% of TRUTAKNA patients versus 28% of placebo
Forgent Power Solutions reported fiscal fourth-quarter 2026 revenue of $462 million, up 94%, and net income of $66 million, compared with a net loss of $4.8 million a year earlier. The company also initiated fiscal 2027 guidance of $2.4 billion to $2.6 billion in revenue, which it said is significantly higher than its IPO forecast.
Q4 fiscal 2026 revenue of $462 million, up 94% year over year; net income of $66 million versus a $4.8 million loss a year earlier
Backlog of $3.0 billion as of June 30, 2026, an all-time high, up 256% year over year
Fiscal 2027 guidance: revenue $2.4 billion to $2.6 billion; adjusted EBITDA $575 million to $625 million; adjusted EPS $1.26 to $1.40
$35 million investment to expand Powertrain Solutions capacity in Tijuana, Mexico, expected to come online in Q4 fiscal 2027
Flex Ltd. appointed George R. Oliver and Mark Eubanks to its board, effective September 24, 2026, and said Amy B. Schwetz will join as Chief Financial Officer of its RMS and ITS segments on October 5, 2026, and is expected to become Flex CFO after the spin-off of its cloud and power infrastructure business. The filing says the spin-off is expected to be completed in the first quarter of calendar 2027, and the board changes are tied to that separation.
George R. Oliver and Mark Eubanks join the Flex board effective September 24, 2026, both as independent directors.
Amy B. Schwetz joins as CFO of the RMS and ITS segments on October 5, 2026, and is expected to serve as Flex CFO after the spin-off.
The spin-off of the cloud and power infrastructure business into Axiom Solutions International, Inc. is expected to be completed in the first quarter of calendar 2027.
Non-management directors receive $90,000 annual cash compensation plus an annual restricted stock unit award with a fair market value of $235,000.
On September 15, 2026, Iridium signed a fourth amendment to its credit agreement, tied to its pending merger with Rocket Lab. The amendment states that the merger will not count as a change of control under the credit agreement, so the term loans can remain outstanding after closing. Certain loan terms become more costly for Iridium only after the merger closes, including higher interest margins, a repricing premium and an exit fee.
The amendment, dated September 15, 2026, is among Iridium, Iridium Satellite LLC, the lenders and Deutsche Bank AG New York Branch as agent.
After closing, term loan rates would be SOFR plus a 2.50% to 3.00% margin, or base rate plus a 1.5% to 2.00% margin, based on Iridium's credit ratings.
After closing, a 1.00% prepayment premium applies to repricing transactions, and a 1.00% exit fee applies to term loans prepaid after the first anniversary of closing.
The merger agreement with Rocket Lab was dated June 28, 2026; the Fourth Amendment's changes take effect only if the merger closes.
Hub Group filed preliminary, unaudited first and second quarter 2026 results and said it expects an operating loss for the first half of 2026 before one-time charges, while revenue is expected to be $1.70 billion to $1.80 billion. The company also said it expects to receive a Nasdaq Staff Delisting Determination, and it plans to request a hearing, because its restated financial statements and delayed 10-K and 10-Q filings are not yet complete, which matters to shareholders because the outcome could affect whether the Class A stock keeps trading on Nasdaq.
Company expects an operating loss for the first half of 2026 before one-time charges; it did not provide an operating income or loss range.
Full-year 2026 consolidated operating revenue is estimated at $3.6 billion to $3.8 billion.
Nasdaq exception to file delayed reports ran through September 14, 2026; the company expects to complete the filings in the fourth quarter of 2026.
David Yeager returned as Chairman and CEO; Patrick O'Donnell will become CFO after the 2025 Form 10-K is filed.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.